Advertisement

International Journal of Hematology

, Volume 105, Issue 5, pp 686–691 | Cite as

HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy

  • Masatoshi TakagiEmail author
  • Yasuyoshi Ishiwata
  • Yuki Aoki
  • Satoshi Miyamoto
  • Akihiro Hoshino
  • Kazuaki Matsumoto
  • Akira Nishimura
  • Mari Tanaka
  • Masakatsu Yanagimachi
  • Noriko Mitsuiki
  • Kohsuke Imai
  • Hirokazu Kanegane
  • Michiko Kajiwara
  • Kanako Takikawa
  • Tsukasa Mae
  • Osamu Tomita
  • Junya Fujimura
  • Masato Yasuhara
  • Daisuke Tomizawa
  • Shuki Mizutani
  • Tomohiro Morio
Original Article

Abstract

Haploidentical hematopoietic cell transplantation (HCT) conditioning with clofarabine and target area under the blood concentration–time curve (AUC)-based busulfan adjustment was performed in three patients with refractory pediatric leukemia. The target AUC for two patients who had already received multiple transplantations was 3600 and 4000 μmol min/L, and that for the patient with Down’s syndrome was 3000 μmol min/L. Regimen-related toxicity was well tolerated in all cases. All three maintained cytological remission throughout the follow-up period (between 31 and 167 weeks). Thus, haploidentical HCT conditioning with clofarabine and target AUC-based busulfan adjustment may be a preferable option for children with recurrent or refractory pediatric leukemia.

Keywords

Haploidentical hematopoietic cell transplantation Clofarabine Busulfan Pediatric refractory leukemia 

Notes

Compliance of ethical standards

Conflict of interest

Masatoshi Takagi received aid for post-marketing surveillance from Sanofi. The remaining authors have no conflict of interest to disclose.

References

  1. 1.
    Inagaki J, Fukano R, Noguchi M, Kurauchi K, Tanioka S, Okamura J. Hematopoietic stem cell transplantation following unsuccessful salvage treatment for relapsed acute lymphoblastic leukemia in children. Pediatr Blood Cancer. 2015;62:674–9. doi: 10.1002/pbc.25353.CrossRefPubMedGoogle Scholar
  2. 2.
    Poon LM, Bassett R Jr, Rondon G, Hamdi A, Qazilbash M, Hosing C, et al. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant. 2013;48:666–70. doi: 10.1038/bmt.2012.195.CrossRefPubMedGoogle Scholar
  3. 3.
    Chevallier P, Labopin M, Buchholz S, Ganser A, Ciceri F, Lioure B, et al. Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol. 2012;89:214–9. doi: 10.1111/j.1600-0609.2012.01822.x.CrossRefPubMedGoogle Scholar
  4. 4.
    Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, et al. Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1819–26. doi: 10.1016/j.bbmt.2012.06.010.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, et al. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood. 2011;118:4258–64. doi: 10.1182/blood-2011-06-358010.CrossRefPubMedGoogle Scholar
  6. 6.
    Watanabe E, Nishikawa T, Ikawa K, Yamaguchi H, Abematsu T, Nakagawa S, et al. Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients. Int J Hematol. 2015;102:611–6. doi: 10.1007/s12185-015-1853-6.CrossRefPubMedGoogle Scholar
  7. 7.
    Aoki Y, Miyawaki R, Imai K, Takagi M, Kajiwara M, Ishiwata Y, et al. Haploidentical bone marrow transplantation with clofarabine and busulfan conditioning for a child with multiple recurrent acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2016;38:e39–41. doi: 10.1097/MPH.0000000000000454.CrossRefPubMedGoogle Scholar
  8. 8.
    Bleyzac N, Barou P, Aulagner G. Rapid and sensitive high-performance liquid chromatographic method for busulfan assay in plasma. J Chromatogr B Biomed Sci Appl. 2000;742:427–32.CrossRefPubMedGoogle Scholar
  9. 9.
    Jeha S, Razzouk B, Rytting M, Rheingold S, Albano E, Kadota R, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 2009;27:4392–7. doi: 10.1200/JCO.2008.18.8706.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG, Borowitz MJ, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118:6043–9. doi: 10.1182/blood-2011-08-374710.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8:468–76.CrossRefPubMedGoogle Scholar
  12. 12.
    Ryu SG, Lee JH, Choi SJ, Lee JH, Lee YS, Seol M, et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007;13:1095–105. doi: 10.1016/j.bbmt.2007.06.005.CrossRefPubMedGoogle Scholar
  13. 13.
    Ward J, Kletzel M, Duerst R, Fuleihan R, Chaudhury S, Schneiderman J, et al. Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. Biol Blood Marrow Transplant. 2015;21:1612–21. doi: 10.1016/j.bbmt.2015.05.017.CrossRefPubMedGoogle Scholar
  14. 14.
    Bartelink IH, Bredius RG, Ververs TT, Raphael MF, van Kesteren C, Bierings M, et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:88–98. doi: 10.1016/j.bbmt.2007.09.015.CrossRefPubMedGoogle Scholar
  15. 15.
    Gonzalez-Vicent M, Molina B, Perez A, Diaz MA. Once-daily intravenous busulfan for 47 pediatric patients undergoing autologous hematopoietic stem cell transplantation: a single center study. J Pediatr Hematol Oncol. 2012;34:180–3. doi: 10.1097/MPH.0b013e3182431e1b.CrossRefPubMedGoogle Scholar
  16. 16.
    Pasquini MC, Le-Rademacher J, Zhu X, Artz A, DiPersio J, Fernandez HF, et al. Intravenous busulfan-based myeloablative conditioning regimens prior to hematopoietic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2016;22:1424–30. doi: 10.1016/j.bbmt.2016.04.013.CrossRefPubMedGoogle Scholar
  17. 17.
    Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, et al. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;. doi: 10.1038/bmt.2016.188.PubMedCentralGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Masatoshi Takagi
    • 1
    Email author
  • Yasuyoshi Ishiwata
    • 2
  • Yuki Aoki
    • 3
  • Satoshi Miyamoto
    • 1
  • Akihiro Hoshino
    • 1
  • Kazuaki Matsumoto
    • 1
  • Akira Nishimura
    • 1
  • Mari Tanaka
    • 1
  • Masakatsu Yanagimachi
    • 1
  • Noriko Mitsuiki
    • 1
  • Kohsuke Imai
    • 1
  • Hirokazu Kanegane
    • 1
  • Michiko Kajiwara
    • 4
  • Kanako Takikawa
    • 2
  • Tsukasa Mae
    • 2
  • Osamu Tomita
    • 5
  • Junya Fujimura
    • 5
  • Masato Yasuhara
    • 6
  • Daisuke Tomizawa
    • 7
  • Shuki Mizutani
    • 1
  • Tomohiro Morio
    • 1
  1. 1.Department of Pediatrics and Developmental BiologyTokyo Medical and Dental University (TMDU)TokyoJapan
  2. 2.Department of Hospital PharmacyTokyo Medical and Dental University (TMDU)TokyoJapan
  3. 3.Department of Pediatric OncologyNational Cancer Research CenterTokyoJapan
  4. 4.Department of Transfusion MedicineTokyo Medical and Dental University (TMDU)TokyoJapan
  5. 5.Department of Pediatrics and Adolescent MedicineJuntendo University, School of MedicineTokyoJapan
  6. 6.Department of Pharmacokinetics and PharmacodynamicsTokyo Medical and Dental University (TMDU)TokyoJapan
  7. 7.Division of Leukemia and Lymphoma, Children’s Cancer CenterNational Center for Child Health and DevelopmentTokyoJapan

Personalised recommendations